{"pageProps":{"initialStudiesData":{"page":{"totalFilteredElements":75},"studies":[{"active":true,"description":"Preoperative FOLFOX versus postoperativ risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized Phase III Trial of the German Rectal Cancer Study Group.","eudractNumber":"2018-001356-35","id":5571,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":"NCT04495088","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-04-16T10:14:02+02:00","shortTitle":"ACO/ARO/AIO-18.2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Niraparib vs. Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicenter randomised phase III trial)","eudractNumber":"2024-516066-11-00","id":8116,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"}],"mutations":[],"nctNumber":"NCT05009082","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2022-10-21T12:11:09+02:00","shortTitle":"AGO-Ovar 28","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"Prospektive, randomisierte, offene, multizentrische Phase II Studie zur Untersuchung der Wirksamkeit von Tifluridin/Tipiracil plus Panitumumab im Vergleich zu Tifluridin/ Tipiracil plus Bevacizumab bei der Erstlinientherapie des metastasierten kolorektalen Karzinoms","eudractNumber":"2019-004223-20","id":7571,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[{"name":"ras-Gen","id":"mt_28"}],"nctNumber":"NCT05007132","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2021-12-09T09:07:50+01:00","shortTitle":"AIO-KRK/YMO-0519 (Fire-8)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"International cooperative study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of vinblastine<br />","eudractNumber":"2017-002935-40","id":4034,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped2","name":"Lymphome"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[{"name":"ALK","id":"mt_11"}],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-04-14T09:44:08+02:00","shortTitle":"ALCL-VBL","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>ALL SCT FORUM Registry 2022</div><div>Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia</div>","eudractNumber":null,"id":9804,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2024-10-01T08:39:44+02:00","shortTitle":"ALL SCT FORUM Registry 2022","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A\nPhase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in\ncombination with Durvalumab, Carboplatin and Etoposide versus Durvalumab,\nCarboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer\n(DeLLphi-312)","eudractNumber":"2024-520050-38","id":10677,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"}],"mutations":[],"nctNumber":"NCT07005128","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-30T12:23:23+02:00","shortTitle":"AMG 757 20240178 (DeLLphi-312)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Randomized, placebo controlled Phase III Study of Induction and Consolidation chemotherapy with Venetoclax in adult patients with newly diagnosed acute myeloid Leukemia or Myelodyspalstic syndrome with ecxess Blasts-2","eudractNumber":"2023-507518-28-00","id":11260,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT04628026","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-08-05T09:00:15+02:00","shortTitle":"AMLSG 31-19","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A\nPhase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig\nor Pembrolizumab Monotherapy for the First-line Treatment of Patients with\nPD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)","eudractNumber":"2024-517780-24-00","id":10715,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06868277","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-30T10:57:06+01:00","shortTitle":"ARTEMIDE-Lung04","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<p style=\"margin:0in;\">An open label Phase\nII randomized trial of BNT113 in\ncombination with pembrolizumab versus\npembrolizumab monotherapy as a first line therapy in patients with\nunresectable recurrent, or metastatic Head and Neck Squamous Cell\nCarcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+)\nand expresses PD-L1&#160;(AHEAD-MERIT)</p>","eudractNumber":"2020-001400-41","id":6731,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"}],"mutations":[{"name":"HPV16","id":"mt_86"},{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT04534205","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2022-04-11T15:21:31+02:00","shortTitle":"BNT113-01 (AHEAD-MERIT)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"<p style=\"line-height:normal;margin-top:0pt;margin-bottom:0pt;margin-left:0in;\">A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the \nEfficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP \nChemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma<br /></p>","eudractNumber":"2023-510178-15","id":10012,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-10-23T10:03:29+02:00","shortTitle":"CA073-1020 GOLSEEK-1","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]},"initialUrl":"/api/studies?lang=de&page=0&size=10&tls=tl_1","jsonDlt":"{\"name\":\"Studien des CCC Mainfranken\",\"numberOfItems\":10,\"itemListElement\":[{\"position\":1,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Preoperative FOLFOX versus postoperativ risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized Phase III Trial of the German Rectal Cancer Study Group.\",\"name\":\"ACO/ARO/AIO-18.2\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/5571\"}},{\"position\":2,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Niraparib vs. Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicenter randomised phase III trial)\",\"name\":\"AGO-Ovar 28\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/8116\"}},{\"position\":3,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Prospektive, randomisierte, offene, multizentrische Phase II Studie zur Untersuchung der Wirksamkeit von Tifluridin/Tipiracil plus Panitumumab im Vergleich zu Tifluridin/ Tipiracil plus Bevacizumab bei der Erstlinientherapie des metastasierten kolorektalen Karzinoms\",\"name\":\"AIO-KRK/YMO-0519 (Fire-8)\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/7571\"}},{\"position\":4,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"International cooperative study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of vinblastine<br />\",\"name\":\"ALCL-VBL\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/4034\"}},{\"position\":5,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"<div>ALL SCT FORUM Registry 2022</div><div>Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia</div>\",\"name\":\"ALL SCT FORUM Registry 2022\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9804\"}},{\"position\":6,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A\\nPhase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in\\ncombination with Durvalumab, Carboplatin and Etoposide versus Durvalumab,\\nCarboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer\\n(DeLLphi-312)\",\"name\":\"AMG 757 20240178 (DeLLphi-312)\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10677\"}},{\"position\":7,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Randomized, placebo controlled Phase III Study of Induction and Consolidation chemotherapy with Venetoclax in adult patients with newly diagnosed acute myeloid Leukemia or Myelodyspalstic syndrome with ecxess Blasts-2\",\"name\":\"AMLSG 31-19\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11260\"}},{\"position\":8,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A\\nPhase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig\\nor Pembrolizumab Monotherapy for the First-line Treatment of Patients with\\nPD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)\",\"name\":\"ARTEMIDE-Lung04\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10715\"}},{\"position\":9,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"<p style=\\\"margin:0in;\\\">An open label Phase\\nII randomized trial of BNT113 in\\ncombination with pembrolizumab versus\\npembrolizumab monotherapy as a first line therapy in patients with\\nunresectable recurrent, or metastatic Head and Neck Squamous Cell\\nCarcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+)\\nand expresses PD-L1&#160;(AHEAD-MERIT)</p>\",\"name\":\"BNT113-01 (AHEAD-MERIT)\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/6731\"}},{\"position\":10,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"<p style=\\\"line-height:normal;margin-top:0pt;margin-bottom:0pt;margin-left:0in;\\\">A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the \\nEfficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP \\nChemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma<br /></p>\",\"name\":\"CA073-1020 GOLSEEK-1\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10012\"}}],\"url\":\"https://cccmf-studien-homepage.vercel.app/studies?page=1&tls=tl_1\"}","__lang":"de","__namespaces":{"common":{"app_title":"Comprehensive Cancer Center Mainfranken Studiendatenbank","app_description":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","app_version":"Version","central_contacts":"Ihre Ansprechpartnerin im CCC MF","email_label":"E-Mail","contact_info_email":"anmeldung_ccc@ukw.de","contact_info_email_title":"E-Mail der Anmeldung des Comprehensive Cancer Center Mainfranken","fax_label":"Fax","contact_info_fax_number":"+49 931 201-35359","contact_info_fax_number_title":"Faxnummer des Comprehensive Cancer Center Mainfranken","phone_label":"Tel.","contact_info_phone_number":"+49 931 201-35350","contact_info_phone_number_title":"Telefonnummer des Comprehensive Cancer Center Mainfranken","website_label":"Webseite","contact_info_website":"https://www.med.uni-wuerzburg.de/ccc/startseite/","contact_info_website_title":"Webseite des Comprehensive Cancer Center Mainfranken","comprehensive_cancer_center_mainfranken_cccmf":"Comprehensice Cancer Centers Mainfranken (CCC MF)","profile_picture_alt_text":"Foto von {{ name }}","close_menu_title":"Studienfilter ausblenden","open_menu_title":"Studienfilter einblenden","search_button_label":"Suchen","text_field_search_label":"Suche...","text_field_clear_buton_title":"Textfeld leeren","hide_filter_button_text":"Filter ausblenden","show_filter_button_text":"Filtern","back_url_title":"Zurück","imprint":"Impressum","data_protection":"Datenschutz","accessibility":"Barrierefreiheit","studies_list_breadcrumb_label":"Studienliste","tree_view_check_boxes_number_of_studies":"{{numberOfStudies}} Treffer, wenn dieser Filter aktiviert wird","footer_logo_ccc_title":"Zur Webseite des CCC Mainfranken","footer_logo_ozw_title":"Zur Webseite des Onkologischen Zentrums Würzburg","footer_logo_ukw_title":"Zur Webseite des Universitätsklinikums Würzburg","footer_logo_isz_ectu_title":"Zur Webseite des Interdisziplinären Studienzentrums mit ECTU","loading":"Laden...","landing_page_name":"Startseite","theme_dark":"Hell","theme_light":"Dunkel","study_status_active":"Rekrutierung läuft","study_status_inactive":"Rekrutierung beendet"},"filters":{"includeinactive":"Nicht rekrutierende Studien auch anzeigen","indications":"Nach Erkrankungen filtern","isonly":"Nur Therapiestudien anzeigen","therapy_lines":"Nach Therapielinien filtern","mutations":"Nach molekularen Markern filtern","organizations":"Nach studienaktiven Standorten filtern","phases":"Nach Phasen filtern","reset_filter":"Filter zurücksetzen","filters_selected_alert_message":"Filter aktiv","reset_all_filters":"Filter zurücksetzen","close_filters_menu":"Zurück zu den Suchergebnissen"},"home":{"banner_alt":"Logo des Comprehensive Cancer Center Mainfranken","logo_alt":"Logo des Comprehensive Cancer Center Mainfranken","subtitle":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","title":"CCC MF Studiendatenbank"},"paginatedList":{"number_of_items_found_text":"Seite {{page}} - Studien {{start}} bis {{end}} von insgesamt {{total}}","no_items_found":"Es wurden keine Einträge gefunden.","pagination_item_aria_label_current_page":"Aktuelle Seite, Seite {{page}}","pagination_item_aria_label_page":"Zu Seite {{page}} navigieren","pagination_item_aria_label_next_page":"Zur nächsten Seite, Seite {{page}} navigieren","pagination_item_aria_label_previous_page":"Zur vorherigen Seite, Seite {{page}} navigieren"},"studiesList":{"alert_text":"Hier finden Sie grundlegende Angaben zu klinischen Studien des ","button_aria_label_details":"Zu den Details der Studie {{shortTitle}}","button_label_details":"Mehr Informationen","indications":"Indikationen","mutations":"Molekulare Marker"}}},"__N_SSP":true}